On Mar. 14, 2024, the U.S. Food and Drug Administration approved Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. Rezdiffra received Breakthrough Therapy, Fast Track and Priority Review designations for this indication.

NASH is a result of the progression of nonalcoholic fatty liver disease where liver inflammation, over time, can lead to liver scarring and liver dysfunction. NASH is often associated with other health problems such as high blood pressure and type 2 diabetes.